HCPCS Level II J9326: Injection, telisotuzumab vedotin-tllv, 1 mg
HCPCS Level II code J9326 describes the medication administration unit for telisotuzumab vedotin-tllv, billed per 1 mg of the injectable oncology drug; the service represents dispensing and preparation of the intravenous antineoplastic agent typically provided in oncology infusion centers or hospital outpatient infusion clinics as part of systemic cancer therapy.
For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.
Customize your policy alerts
Sign up for hcpcs J9326 policy alerts
Get alerted when payer policies referencing J9326 are released or updated.
Monitor payer policy activity